Thrombotic thrombocytopenic purpura is a rare blood disorder where unwanted blood clots form throughout the body, using up platelets and red blood cells, leading to serious complications that affect the brain, kidneys, and heart—yet with timely treatment, many patients can manage this condition and return to their daily lives.

Understanding Treatment Goals in Thrombotic Thrombocytopenic Purpura

When someone receives a diagnosis of thrombotic thrombocytopenic purpura, often shortened to TTP, the main goal of treatment is to stop the dangerous formation of blood clots in the smallest blood vessels before they cause permanent damage to vital organs. This rare blood disorder requires immediate medical attention because without treatment, it can quickly become life-threatening. The approach to managing TTP depends heavily on whether the condition appeared suddenly or was inherited from birth, as well as on the patient’s overall health and how severe the symptoms have become.^[1]

Medical professionals work to restore normal levels of an important enzyme called ADAMTS13, which normally prevents platelets from clumping together unnecessarily. When this enzyme isn’t working properly or is present in very low amounts, platelets stick together and form clots that block blood flow to organs like the brain, kidneys, and heart. Treatment also aims to manage complications such as anemia (low red blood cell count), thrombocytopenia (low platelet count), and organ damage that may have already occurred.^[2]

There are established, guideline-approved treatments that have been used successfully for many years, and these remain the backbone of TTP care. At the same time, researchers continue to explore new therapies through clinical trials, seeking ways to make treatment more effective, reduce the need for repeated procedures, and prevent the condition from coming back. The treatment landscape includes both immediate emergency interventions and longer-term strategies to keep patients healthy and prevent future episodes.^[4]

Standard Treatment Approaches for TTP

The cornerstone of TTP treatment is a procedure called plasma exchange, also known as plasmapheresis. During this procedure, doctors remove blood from the patient’s body, separate out the liquid portion called plasma, and replace it with fresh frozen plasma from healthy donors. This fresh plasma contains the ADAMTS13 enzyme that the patient’s body is lacking or that antibodies have been blocking. The plasma exchange procedure typically needs to be performed daily until the patient’s platelet count returns to normal and symptoms improve, which can take several days to weeks.^[4]

Fresh frozen plasma used in these exchanges comes from carefully screened donors and provides the missing enzyme activity. In some medical centers, doctors use a specially treated plasma product called Octaplas, which has undergone a solvent detergent process to reduce the risk of transmitting infections. This pooled plasma product from multiple donors offers an alternative to single-donor plasma while maintaining safety and effectiveness.^[9]

When plasma exchange facilities are not immediately available, doctors may start with simple plasma infusion as a temporary measure until the patient can be transferred to a center equipped to perform full plasma exchange. However, plasma exchange remains superior to simple infusion because it not only provides the needed ADAMTS13 enzyme but also removes the harmful antibodies that may be blocking the enzyme’s function.^[9]

Alongside plasma exchange, patients typically receive medications that suppress the immune system. Corticosteroids, such as prednisone or methylprednisolone, are commonly given to reduce the production of antibodies that attack ADAMTS13. These medications help calm down the immune system’s mistaken attack on the body’s own enzyme. Corticosteroids can be given as pills or through an intravenous line, depending on how sick the patient is and how quickly treatment needs to work.^[10]

Another important medication used in TTP treatment is rituximab, which is a type of antibody-based drug that targets specific immune cells called B cells. These B cells are responsible for producing the antibodies that interfere with ADAMTS13. By reducing the number of B cells, rituximab helps prevent the production of harmful antibodies. This medication is often given during the initial treatment phase and may also be used to prevent TTP from coming back after the first episode has been controlled.^[9]

The therapy duration varies from patient to patient. Daily plasma exchange typically continues until the platelet count has been normal for at least two consecutive days and other blood markers show improvement. Some patients may need treatment for just a few days, while others require weeks of daily procedures. After the acute phase, patients often continue taking immunosuppressive medications for several months to prevent relapse. Regular blood tests to monitor ADAMTS13 levels and platelet counts help doctors decide when it’s safe to reduce or stop treatment.^[11]

Side effects from plasma exchange can include allergic reactions to the donor plasma, low calcium levels causing tingling or muscle cramps, and problems with the large intravenous catheter needed for the procedure, such as infection or blood clots. Corticosteroids may cause increased appetite, weight gain, high blood sugar, mood changes, and trouble sleeping. With rituximab, patients may experience infusion reactions during the medication administration, and there’s an increased risk of infections because the immune system is suppressed. Despite these potential side effects, the benefits of treatment far outweigh the risks in this life-threatening condition.^[9]

For patients with the inherited form of TTP, called congenital TTP or Upshaw-Schulman syndrome, the treatment approach differs somewhat. These patients don’t have antibodies attacking ADAMTS13; instead, they were born unable to produce enough of the enzyme. They typically need regular infusions of fresh frozen plasma to replace the missing enzyme, but they don’t need the immune-suppressing medications. The frequency of plasma infusions depends on the individual patient’s needs—some require them regularly throughout life, while others with milder cases need treatment only during stressful situations like illness or pregnancy.^[9]

Treatment in Clinical Trials

Medical research has brought exciting advances in TTP treatment through clinical trials testing new and innovative therapies. One of the most significant recent developments is caplacizumab, sold under the brand name Cablivi, which represents a completely new approach to treating TTP. This medication is a specialized type of antibody fragment called a nanobody that works by blocking von Willebrand factor, a protein that helps platelets stick together. By preventing this protein from working, caplacizumab stops platelets from forming unwanted clots even when ADAMTS13 levels are still low.^[4]

Caplacizumab has completed Phase III clinical trials, which represent the final stage of testing before a medication can be approved for widespread use. In these studies, researchers compared patients receiving caplacizumab along with standard plasma exchange and immunosuppression to those receiving only standard treatment. The results showed that patients who received caplacizumab had faster recovery of their platelet counts and needed fewer days of plasma exchange. They also had a lower rate of TTP coming back during the treatment period. Based on these positive results, regulatory authorities have approved caplacizumab for use in acquired TTP in combination with plasma exchange and immunosuppressive therapy.^[4]

The mechanism of action for caplacizumab is quite specific. Von Willebrand factor normally exists as large chains of protein molecules that grab onto platelets and help them form clots when needed. In TTP, because ADAMTS13 isn’t breaking down these large chains into smaller pieces, they become extremely sticky and cause inappropriate clotting. Caplacizumab works by attaching to von Willebrand factor and blocking the spot where it would normally bind to platelets. This prevents the formation of clots in small blood vessels without stopping normal blood clotting when the body actually needs it.^[4]

Another groundbreaking therapy being studied in clinical trials is recombinant ADAMTS13, known by the brand name Adzynma. This is a laboratory-made version of the enzyme that patients with congenital TTP lack. Rather than needing regular plasma infusions from donors, patients could receive this engineered enzyme replacement therapy. In 2023, regulatory authorities approved recombinant ADAMTS13 specifically for patients with congenital TTP, both for regular preventive treatment and for on-demand use when symptoms appear.^[9]

The clinical trial data for recombinant ADAMTS13 came from Phase III studies where patients with congenital TTP were given either the recombinant enzyme or traditional plasma-based therapies. The results were striking: during an average follow-up period of about 13 months, none of the 38 patients receiving recombinant ADAMTS13 as preventive therapy experienced an acute TTP episode. In contrast, patients using plasma-based therapies did experience some acute episodes. Additionally, patients on recombinant ADAMTS13 had no subacute TTP events, while several patients on plasma therapy did. This suggests that enzyme replacement with the recombinant product may provide better disease control than traditional plasma infusions.^[9]

The advantage of recombinant ADAMTS13 is significant. Because it’s manufactured in a controlled laboratory setting rather than collected from human donors, there’s no risk of transmitting blood-borne infections. It also provides a standardized, predictable amount of enzyme with each dose, unlike donor plasma where enzyme levels can vary. For patients who need lifelong treatment, this offers both greater safety and convenience. The medication can be given as an infusion, and treatment schedules are individualized based on each patient’s specific needs and disease severity.^[9]

Clinical trials are also exploring the optimal use of rituximab, examining whether giving it earlier in treatment or using it preventively in patients at high risk of relapse might improve outcomes. Some studies are testing whether rituximab can be used as maintenance therapy in lower doses after the acute episode has been controlled, reducing the chance that TTP will come back. These trials are being conducted at medical centers across the United States, Europe, and Japan, with researchers working to standardize treatment guidelines based on the best available evidence.^[11]

Patient eligibility for clinical trials typically depends on several factors. For trials testing treatments for acute acquired TTP, patients usually need to have confirmed low ADAMTS13 activity levels, typically less than 10% of normal. They must not have other conditions that could explain their symptoms, such as cancer or infections causing similar blood abnormalities. For trials testing preventive treatments, patients may need to have had at least one previous TTP episode and show evidence of persistent ADAMTS13 deficiency or ongoing antibody production. Age requirements vary by study, with some trials enrolling only adults while others include children and adolescents.^[9]

The locations of clinical trials span multiple countries and continents. Major medical centers in the United States, particularly academic hospitals with specialized hematology programs, frequently conduct TTP research. European countries including the United Kingdom, France, and Germany have active trial sites. Japan has its own research network for TTP, with specific treatment guidelines developed for Japanese patients. Patients interested in participating in clinical trials should discuss options with their hematology team, who can help identify appropriate studies and facilitate enrollment.^[11]

Most common treatment methods

• Plasma Exchange Therapy
  • Daily removal of patient’s plasma and replacement with fresh frozen plasma containing ADAMTS13 enzyme
  • Continues until platelet count normalizes and symptoms improve, typically taking several days to weeks
  • May use standard fresh frozen plasma or specially treated Octaplas product
  • Considered the gold standard and first-line treatment for acute TTP episodes
• Immunosuppressive Medications
  • Corticosteroids (prednisone, methylprednisolone) to reduce antibody production against ADAMTS13
  • Rituximab, an antibody-based drug that targets B cells responsible for producing harmful antibodies
  • Used during acute treatment and may continue for months to prevent relapse
  • Help calm the immune system’s mistaken attack on the body’s own enzyme
• Enzyme Replacement Therapy
  • Regular plasma infusions for patients with congenital TTP who cannot produce ADAMTS13
  • Recombinant ADAMTS13 (Adzynma), a laboratory-made enzyme approved in 2023 for congenital TTP
  • Provides the missing enzyme without risk of infection transmission
  • Can be given as preventive therapy or on-demand during symptom flares
• Targeted Biological Therapy
  • Caplacizumab (Cablivi), a nanobody that blocks von Willebrand factor from binding to platelets
  • Used in combination with plasma exchange and immunosuppression for acquired TTP
  • Speeds up platelet count recovery and reduces the number of plasma exchange sessions needed
  • Lowers the rate of TTP recurrence during treatment period